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ABSTRACT
In this work, we consider the problem of predicting the
course of a progressive disease, such as cancer or Alzheimer’s.
Progressive diseases often start with mild symptoms that
might precede a diagnosis, and each patient follows their
own trajectory. Patient trajectories exhibit wild variability,
which can be associated with many factors such as geno-
type, age, or sex. An additional layer of complexity is that,
in real life, the amount and type of data available for each
patient can differ significantly. For example, for one patient
we might have no prior history, whereas for another patient
we might have detailed clinical assessments obtained at mul-
tiple prior time-points. This paper presents a probabilistic
model that can handle multiple modalities (including im-
ages and clinical assessments) and variable patient histories
with irregular timings and missing entries, to predict clini-
cal scores at future time-points. We use a sigmoidal func-
tion to model latent disease progression, which gives rise
to clinical observations in our generative model. We imple-
mented an approximate Bayesian inference strategy on the
proposed model to estimate the parameters on data from
a large population of subjects. Furthermore, the Bayesian
framework enables the model to automatically fine-tune its
predictions based on historical observations that might be
available on the test subject. We applied our method to
a longitudinal Alzheimer’s disease dataset with more than
3000 subjects [23] and present a detailed empirical analy-
sis of prediction performance under different scenarios, with
comparisons against several benchmarks. We also demon-
strate how the proposed model can be interrogated to glean
insights about temporal dynamics in Alzheimer’s disease.
1. INTRODUCTION
Many progressive disorders, such as Alzheimer‘s disease (AD)
[3] or cancer [15], begin with mild symptoms that often pre-
cede diagnosis, and follow a patient-specific clinical trajec-
tory that can be influenced by genetic and/or other factors.
Therapeutic interventions, if available, are usually more ef-
fective in the earliest stages of a progressive disease [1].
Therefore, tracking and predicting disease progression, par-
ticularly during the mild stages, is one of the primary ob-
jectives of personalized medicine.
In this paper, we are motivated by the real-world clinical
setting where each individual is at risk and thus monitored
for a specific progressive disease, such as AD. Furthermore,
we assume that each individual might pay zero, one, or more
visits to the clinic. In each clinical visit, various biomark-
ers or assessments (correlated with the disease and/or its
progression) are obtained. Example biomarker modalities
include brain MRI scans, PET scans, blood tests, and cog-
nitive test scores. The number and timing of the visits, and
the exact types of data collected at each visit can be planned
to be standardized, but often vary wildly between patients
in practice [4]. An ideal clinical prediction tool should be
able to deal with this heterogeneity and compute accurate
forecasts for arbitrary time horizons.
We present a probabilistic disease progression model that
elegantly handles the aforementioned challenges of longitu-
dinal clinical settings: data missingness, variable timing and
number of visits, and multi-modal data (i.e., data of differ-
ent types). The backbone of our model is a latent sigmoidal
curve that captures the dynamics of the unobserved pathol-
ogy, which is reflected in time-varying clinical assessments.
Sigmoid curves are conceptually useful abstractions that fit
well a wide range of dynamic physical and biological phe-
nomena, including disease progression [11; 27; 25], which
exhibit a floor and ceiling effect. In our framework, the sig-
moid allows us to model the temporal correlation in longi-
tudinal measurements and capture the dependence between
the different tests and assessments, which are assumed to be
generated conditionally independently from the latent state.
We implemented an approximate Bayesian inference strat-
egy on the proposed model and applied it to a large-scale
longitudinal Alzheimer’s disease dataset [23], a devastating,
terminal neurodegenerative disease that affects over 10% of
the population older than 65.
In our experiments, we considered three target variables,
which are widely used cognitive and clinical assessments
associated with AD: the Mini Mental State Examination
(MMSE) [16], the Alzheimer’s Disease Assessment Scale Cog-
nitive Subscale (ADAS-COG) [5], and the Clinical Dementia
Rating Sum of Boxes (CDR-SB) [22]. We trained and evalu-
ated the proposed model on a longitudinal dataset with more
than 3,000 subjects that included healthy controls (cogni-
tively normal elderly individuals), subjects with mild cogni-
tive impairment (MCI, a clinical stage that indicates high
risk for dementia), and patients with AD. These clinical
classifications are done in part based on the three target
biomarkers in our model: MMSE, ADAS-Cog, and CDR-
SB. Over the 5+ year follow-up period of the study, many
of the subjects transitioned between clinical categories, e.g.,
from healthy to MCI or from MCI to AD. In fact, predict-
ing these transitions is a significant focus of prior literature.
ar
X
iv
:1
80
3.
05
01
1v
1 
 [c
s.L
G]
  1
3 M
ar 
20
18
Yet, the emphasis in prior work is in what might be called
static prediction: the target variable is pre-fixed, e.g., [31;
18]. For example, a common objective is to discriminate
MCI subjects who progress to AD within some time win-
dow, e.g., 2 years. Similar problem setups are popular in
cancer research, where a question of interest might be the 5
year survival. This is a binary classification problem. Our
objective, on the the other hand, is to model and predict the
entire clinical trajectory. Furthermore, we want to achieve
this with a model that enables knowledge discovery about
the progression of the disease.
We provide a detailed analysis of prediction accuracy achieved
with the proposed model and alternative benchmark meth-
ods under different scenarios that involve varying the past
available visits and future time windows. In all our com-
parisons, the proposed model achieves significantly and sub-
stantially better accuracy for all target biomarkers. Further-
more, due to the probabilistic and generative nature of our
model, we are able to make certain mechanistic queries to
gain further insights about the underlying dynamics. This
perspective offers us some new insights. For instance, we
provide a quantification of the impact of AD risk factors
(such as APOE genotype) on disease progression.
The rest of this paper is organized as follows. Section 2
presents the proposed model and inference method. Section
3 describes the data and experimental set-up. Then, we
present empirical results in Section 4. Finally, we conclude
in Section 5.
2. PROPOSED METHOD
Figure 1: Left: Graphical model (Bayesian network) that
depicts the assumed statistical dependency structure be-
tween random variables (circles) and model parameters
(rectangles). We use standard conventions: shaded random
variables are assumed to be observed during training, and
plates indicate replication with the number of copies listed at
the lower left corner. See text for information on variables.
Right: Illustration of sigmoids (with two different inflection
points) that are assumed to model latent progression curves
of two target variables.
2.1 Model
Let us first describe our notation and present our model.
Assume we are given n subjects. xi ∈ Rd×1 denotes sub-
ject i’s d-dimensional attribute vector. In our experiments,
this vector contains APOE genotype (encoded as number
of E4 alleles, which can be 0, 1 or 2) [7], education (in
years) [12], sex (0 for female and 1 for male) [9] and two well-
established neuroanatomical biomarkers of AD computed
from a baseline MRI scan (namely total hippocampal [10]
and ventricular volume [20] normalized by brain size). The
MRI biomarkers capture so-called “brain reserve” [26]. Let
yki ∈ Rvi×1 represent the values of the the k’th dynamic
(i.e., time-varying) target variable at vi different clinical vis-
its. ti = [ti1, · · · , tivi ] ∈ Rvi×1 denotes a vector of the age of
subject i at these visits. Note that the number and timing
of the visits can vary across subjects. In general, we will
assume k ∈ {1, · · · ,m}. In our experiments, we consider 3
target variables: MMSE, ADAS-COG or CDRSB and thus
m = 3. We use dki = [d
k
i1, · · · , dkivi ] to denote subject i’s
latent trajectory values associated with the k’th target vari-
able. We assume each dkij ∈ [0, 1], with lower values corre-
sponding to milder stages. As we describe below, the target
variable, which is a clinical assessment, will be assumed to
be a noisy observation of this latent variable. We model the
latent trajectory of dki as a sigmoid function of time (i.e.,
age), parameterized by a target- and subject-specific inflec-
tion point pki ∈ R and a subject-specific slope parameter
si ∈ R. Note that we assume that the slopes of the latent
sigmoids associated with each target are coupled for each
subject, yet the inflection points differ, which correspond
to an average lag between the dynamics of target variables.
This is consistent with the hypothesized biomarker trajec-
tories of AD [11]. However, it would be easy to relax this
assumption by allowing each target variable to have its own
slope.
We assume the inflection points {pki } and slopes {si} are
random variables drawn from Gaussian priors with means
equal to linear functions of subject-specific attributes xi:
pki ∼ N (vTxi + ak, σ2p) (1)
si ∼ N (wTxi + b, σ2s), (2)
where ak ∈ R is associated with the k’th target (account-
ing for different time lags between target dynamics), while
v,w ∈ Rd×1, and b, σp, σs ∈ R are general parameters. Here
and henceforth N (µ, σ2) denotes a Gaussian with mean µ
and variance σ2.
Given si and p
k
i , the latent value d
k
ij associated with the
k’th target is computed by evaluating the sigmoid at tij :
dkij =
1
1 + exp(−(tij − pki )si)
.
The inflection point pki marks the age at which the rate of
change achieves its maximum, which is equal to si/4.
Finally, we assume that the target variable value ykij is a
linear function of the latent state dkij corrupted by additive
zero-mean independent Gaussian noise:
ykij ∼ N (ckdkij + hk, σ2k), (3)
where ck, hk, and σk ∈ R are universal (i.e., not subject-
specific) parameters associated with the k’th target variable.
We refer to Eq. (3) as an observation model. Fig. 1 depicts
the dependency relationship between all variables.
2.2 Inference
In this section, we discuss how to train the proposed model
and apply it during test time.
2.2.1 Training
Let us use Θ to denote the parameter set of our model:
Θ = {w, b, σp, σs,v, {ak, ck, hk, σk}k=1,··· ,m}.
The goal of training is to estimate the model parameters
Θ given data from n subjects: {yi,xi, ti}i=1,...,n. Here,
yi = [y
1
i . . .y
m
i ] ∈ Rvi×m denotes m target values of the
ith subject for vi visits. We estimate Θ via maximizing the
likelihood function :
n∏
i=1
P (yi|xi, ti; Θ).
Note that we use the standard notation of p(y|x) to indicate
the probability density function of the random variable Y
(evaluated at y) conditioned on the random variable X tak-
ing on the value x. Also, parameters not treated as random
variables are collected on the right hand side of “;”.
Now, let us focus on the likelihood of each subject:
P (yi|xi, ti; Θ) (4)
=
∫ ∫ [ vi∏
j=1
p(yij |si,pi, tij)
]
p(si,pi|xi; Θ)dsidpi,
with p(si,pi|xi; Θ) = p(si|xi; Θ)p(pi|xi; Θ) due to Eq (1,2).
Instead of the computationally challenging Eq (4), we use
variational approximation [24] and maximize the expected
lower bound objective (ELBO):
F (Θ, {γi}) =
n∑
i=1
Eq(
vi∑
j=1
m∑
k=1
log p(ykij |si, pki , tij ; Θ))
− Eq(log q(si; γi))− Eq(log q(pi; γi)), (5)
where q(si; γi) = N(µsi, σ
2
si) and q(pi; γi)) = N(µpi,Σpi =
ΓTpiΓpi) are proxy distributions that approximate the true
posterior distributions p(si|yi,xi; Θ) and p(pi|yi,xi; Θ), re-
spectively. Recall that pi is m-dimensional since each target
variable is associated with a different inflection point, yet
the slope parameter si is shared across targets and thus a
scalar. We have used γi = {µsi, σsi, µpi,Γpi} to collectively
denote the proxy parameters. The expectation in the first
term is with respect to the proxy distributions and can be
approximated via Monte Carlo sampling. Thus:
Eq(
∑
k
log p(ykij |si, pki , tij ; Θ))
≈ 1
S
S∑
s=1
log p(yij |s(s)i ,p(s)i , tij ; Θ), (6)
where s
(s)
i and p
(s)
i are Monte Carlo samples drawn using
the “re-parameterization trick.” I.e., s
(s)
i = η
(s)σsi + µsi
and p
(s)
i = Γ
T
pi
(s) + µpi, where η
(s) ∈ R and (s) ∈ Rm×1
are realizations of the auxiliary random variables, indepen-
dently drawn from zero-mean standard Gaussians, N(0, 1)
and N(0, I), respectively. The “re-parameterization trick”
allows us to differentiate the ELBO (or more accurately, its
approximation that uses Eq. 6) with respect to γi. E.g.:
∂s
(s)
i
∂σsi
= η(s), and
∂s
(s)
i
∂µsi
= 1.
During training, we use gradient-ascent to iteratively opti-
mize Eq. 5 with respect to Θ and the parameters of the
proxy distributions: {γi}. Note the structure of ELBO is
flexible: missing target variables are treated by ignoring the
corresponding term and the sum is over visits, which can
handle irregular timings. Training yields optimal parame-
ters: Θ∗, and {γ∗i }.
2.2.2 Testing
During test time, we are interested in computing the poste-
rior distribution of yn+1 for a new subject with xn+1 at an
arbitrary time-point (age) t. Note that we drop the second
sub-script, i.e., j index, of yn+1 to emphasize that we will
be computing these posterior probabilities at many differ-
ent (often future) time-points. There are two types of test
subjects: those with no history of visits (scenario 1), and
those with at least one prior clinical visit (scenario 2). For
scenario 2, we will use {y(n+1)j , t(n+1)j}j=1,...,vn+1 to col-
lectively denote the vn+1 historical observations and their
corresponding visit times. Note that we fix Θ∗ to the values
obtained from training.
In scenario 1, we use Eq. (4) to compute the posterior:
P (ykn+1|xn+1, t; Θ∗) (7)
=
∫ ∫
p(ykn+1|s, pk, t; Θ∗)p(s|xn+1; Θ∗)p(pk|xn+1; Θ∗)dsdpk,
where p(s|xi; Θ∗) and p(pk|xi; Θ∗) are defined in Eq (1,2).
In the second scenario, we will first maximize the ELBO
of Equation (5) evaluated for the observations on the new
subject {y(n+1)j , t(n+1)j} and attribute vector: xn+1:
Eq(
vn+1∑
j=1
m∑
k=1
log p(yk(n+1)j |sn+1, pkn+1, t(n+1)j ; Θ∗)
−Eq(log q(sn+1, γn+1))− Eq(log q(pn+1, γn+1)). (8)
Eq (8) is optimized with respect to γn+1, which yields proxy
distributions that can be viewed as approximations:
q(sn+1, γn+1) ≈ p(s|{y(n+1)j , t(n+1)j},xn+1; Θ∗) (9)
q(pn+1, γn+1) ≈ p(pk|{y(n+1)j , t(n+1)j}; Θ∗) (10)
Note that these distributions can be regarded as a cus-
tomization of the priors on s and p given the observed data.
We then proceed to use these approximate q distributions
in Equation (7), replacing p(s|xi; Θ∗) and p(pk|xi; Θ∗), to
evaluate the posterior distribution for an arbitrary time-
point t conditioned on past observations.
During test-time, we often have two distinct objectives: max-
imizing the posterior distribution or drawing samples from it
to estimate the posterior mean and standard deviation. For
the maximization problem, we can approximate the inte-
gral of Eq (7) via a Monte Carlo strategy by drawing sam-
ples from p(s|xi; Θ∗) and p(pk|xi; Θ∗) (Scenario 1) or the
approximate distributions q(sn+1, γn+1) and q(pn+1, γn+1)
(Scenario 2). Finally, one can use an ancestral sampling
strategy to generate samples from the posterior distribu-
tion. Here, we first sample sn+1 and pn+1, either from the
priors of Eq (1) and (2) (Scenario 1) or customized priors of
Eq (9) and (10) (Scenario 2).
3. EXPERIMENTS
3.1 Dataset
We use a dataset of 3,057 subjects (baseline age 73.3± 17.2
years) collected by ADNI [23] to empirically validate and
demonstrate the proposed model. This dataset contained
multiple clinical visits per subject, during which thorough
cognitive and symptomatic assessments were conducted. In
our experiments, we used MMSE, ADAS-COG and CDR-SB
Table 1: Number of subjects per baseline clinical group. The
time interval (mean ± std) between subsequent visits.
Visit Number of Subjects Time From
Number HC MCI AD Prior Visit (mo)
baseline 797 1709 551 N/A
1 611 1070 312 7.4± 21.4
2 450 758 194 8.0± 19.8
3 338 486 92 10.1± 19.2
4 241 331 11 10.5± 18.6
5 155 189 0 11.2± 12.7
6 92 120 0 10.3± 13.2
7 45 59 0 8.9± 7.8
as three target variables. MMSE has a range between 0 (im-
paired) and 30 (healthy), whereas ADAS-COG takes on val-
ues between 0 (healthy) to 70 (severe), and CDR-SB varies
from 0 (healthy) to 18 (severe). The first two (MMSE and
ADAS-COG) are general cognitive assessments that track
and predict dementia, while CDR-SB is a clinical score that
measures the severity of dementia-associated symptoms.
In ADNI, clinical assessment were done every 6-12 months.
The timing of these visits varied and certain subjects missed
visits. Furthermore, most subjects dropped out of the study
by their 4th planned visit. Hence while the clinical follow-up
period spanned over 5 years, each subject had an average
of 3.2 visits. In total, there were 9716 time-points in our
dataset. The subjects ranged from 55 to 95 years of age and
were grouped into three clinical categories: health control
(HC), mild cognitive impairment (MCI), and AD patients.
These clinical categorizations in part relied on the target
variables of interest. Table 1 provides a summary of the dif-
ferent visits and how they breakdown across clinical groups.
During the follow-up period, some subjects transitioned be-
tween categories, resulting in six types of subjects: stable
HC, stable MCI, stable AD, and MCI-to-AD, HC-to-AD,
and HC-to-MCI converters. There were also a very small
number of subjects who improved in clinical categories (e.g.
AD-to-MCI).
In addition to the target variables, we utilized individual-
level traits associated with AD: age, APOE genotype (num-
ber of E4 alleles) [7], sex, and education (in years) [9]. We
also used baseline brain MRI scans to derive two anatomical
biomarkers of AD: total hippocampal and ventricle volume
normalized by brain size. These imaging biomarkers were
automatically computed with FreeSurfer [8] and quality con-
trolled as previously described [19].
Finally, as we describe below, we considered utilizing the
longitudinal imaging biomarkers (hippocampal and ventri-
cle volume) as target variables that were available during
training. This is because ADNI is a unique dataset and at-
tempts to acquire brain MRI scans on each subject every
6-12 months. As a result, we have access to these invalu-
able data. Yet, we emphasize that during test time, we
only considered the availability of MMSE, ADAS-COG and
CDR-SB on historical visits and did not assume longitudinal
neuroimaging data on test subjects.
3.2 Experimental Setup
3.2.1 Benchmark Methods
In our experiments, we compare the proposed method to the
following benchmarks:
1. Global: A 4-parameter (scale, bias, inflection, and
slope) sigmoidal model that was fit on all training data
(least-squares)
2. Sex-specific: Same as above but separate for males and
females
3. APOE-specific: Same as above, but separate for three
groups defined by APOE-E4 allele count {0, 1, 2}.
4. Sex- and APOE-specific: Same as above, but separate
for each sex and APOE group.
5. Linear mixed effects (LME) model: A linear regression
model with subject-specific attributes (xi) as fixed ef-
fects, and time and bias term as a random effects. This
LME model, commonly used to capture longitudinal
dynamics [17; 4], allows each subject to deviate from
the average trajectory determined by its attributes by
shifts in slope and offset.
6. Subject-specific linear model: Least-squares fit of a
linear model on each subject’s historical data. When
there is only one past visit, we adopt a carry-forward
extrapolation.
Benchmarks 1-5 make use of the training data, whereas
benchmark 6 ignores the training data and merely relies
on each test subject’s own data. While benchmark 1-4 use
models that are fixed after training, benchmarks 5 and 6
make adaptations to the model given observations on the
test subject. Below, we refer to benchmarks 1-4 as training-
fixed benchmarks. The LME model (benchmark 5) uses test
observations to estimate subject-specific deviations from a
global linear model. Benchmark 6 fits a line to historical
data of the test subject, and is a widely used technique in
clinical practice. We did not fit a sigmoid to the subject-
specific data as one would need more than 4 historical time-
points to obtain reliable estimates. For benchmarks 1-4, we
also implemented linear versions (i.e. least squares fit of a
line), yet the prediction performance was no better than the
sigmoidal modes. Therefore, we omitted those results due
to space constraints.
3.2.2 Evaluation
For each target variable, we use the mean and standard de-
viation of the absolute error across test subjects to evaluate
the different models. In order to examine the statistical sig-
nificance of the difference between the proposed method and
benchmarks, we used following “paired permutation” strat-
egy. For each test subject, we randomly permuted the labels
of the prediction models. Note that the random permuta-
tion was done at the subject-level, in order to respect the
temporal dependency structure in longitudinal assessments.
Thus, each randomly shuffled model was used to compute
predictions for all time-points of a given subject. For each
permutation, we computed the mean absolute error (MAE,
average across target variables) of the predictions of each
(randomly shuffled) model. Next, we computed and saved
the difference between each model’s MAE and the proposed
model’s MAE. After sorting these differences (in descend-
ing order) over all permutations, the permutation p-value
was computed as the rank of the true difference (i.e. the
difference between the MAE of the benchmark model and
proposed model without permutation) divided by the num-
ber of permutations (10,000) plus 1.
3.2.3 Implementation Details
We implemented the proposed model and inference algo-
rithm in Python 1, using the Edward library [29], which is
in turn built on TensorFlow [2]. We used a 20-fold cross-
validation strategy in all our experiments. We first parti-
tioned the data into 20 non-overlapping, roughly equally-
sized sets of subjects. In each of the 20 folds, we reserved
one of the partitions as the independent test set. Out of the
remaining 19 partitions, one was set aside as a validation set,
while the rest were combined into a training set. The train-
ing set was used to estimate the model parameters, i.e., Θ∗,
while performance on the validation set was used to select
hyper-parameters, such as step size in the optimization and
evaluate random initializations. Finally, test performance
was computed on the test set. We report results averaged
across 20 folds.
3.3 Prediction Results
We first show the quantitative prediction results for all the
methods and three target variables (MMSE, ADAS-COG,
and CDRSB). In the following, we consider several predic-
tion scenarios.
In the first prediction scenario, we vary the number of past
visits available on the test subjects (i.e., vn+1). In general,
we expect this variation to influence the LME and subject-
specific linear model benchmarks (5 and 6), in addition to
the proposed model. These methods fine-tune their predic-
tions based on historical observations available on test data.
With more test observations, we expect them to achieve bet-
ter accuracy. All other benchmarks are fixed after training
and thus their performance should not improve with increas-
ing number of past observations.
In the second scenario, we fix the number of past observa-
tions on test subjects and vary the prediction horizon. In
general, all models’ predictions should be less accurate for
more distant future time-points.
Finally, we focus on the proposed model and consider train-
ing it on longitudinal imaging data available in training.
Brain MRI scans are expensive and hard to obtain, so through-
out this paper we assumed that each test subject has only a
single baseline MRI scan. Yet, the ADNI dataset contains
longitudinal imaging data and we were interested in quan-
tifying the effect of using these during training on test-time
performance.
3.3.1 Varying the Number of Past Visits
Figure 2 shows the MMSE, ADAS-COG and CDRSB pre-
diction accuracies (mean and standard deviation of absolute
error). We observe that the performance of the training-
fixed benchmarks (1-4) worsen slightly as the number of past
visits increases. This is likely because the training data con-
tains more samples at early times (i.e., relatively younger
ages), partially because most subjects drop out by their 4th
visit. Therefore, a model trained on these data is expected
to be less accurate for older ages.
The adaptive benchmarks (5-6) and the proposed model,
1The code of this work is available at
https://github.com/zyy123jy/kdd
on the other hand, overcome this handicap to achieve bet-
ter accuracy with more past visits. As we discussed above,
this is largely because these techniques exploit test obser-
vations to fine-tune their models. The subject-level linear
model (benchmark 6), in fact, is an extreme example, where
the predictions are computed merely by extrapolating from
historical observations without relying on training data.
Finally, we note that the proposed model achieves a sig-
nificantly and substantially better accuracy than all bench-
marks (all paired permutation p-values < pmax = 0.04).
The subject-specific benchmark (6) exhibits the largest vari-
ance implying the quality of performance varies wildly across
subjects. Overall, the training-fixed benchmarks perform
the worst. In general the proposed model’s variance is among
the smallest, indicating consistency in prediction accuracy.
3.3.2 Varying the Time Horizon
In order to evaluate how prediction performance changes as
a function of the time horizon, we evaluated the methods for
different future time-points. In this empirical scenario, we
assume that each test subject has 2 past clinical assessments
(obtained at baseline and month 6). Our goal is to predict
MMSE, ADAS-COG and CDRSB scores at later time-points
(starting at 12 months after baseline, up to 36 months).
Based on the longitudinal study protocol, we considered 6
month intervals and assigned the actual visits to the closest
6-month bucket.
Fig 3 shows prediction accuracies of all considered methods.
The proposed method performs significantly (all paired per-
mutation p-values < pmax = 0.03) and substantially bet-
ter than all other methods, with the difference increasing
from the short term (12 months) to long term (36 months).
For the benchmark models, prediction accuracy tends to
drop more dramatically for longer time horizons. As above,
training-fixed benchmarks perform the worst.
3.3.3 Training with or without longitudinal MRI scans
Since longitudinal MRI scans are available for most sub-
jects in our dataset, we considered the use of serial imaging
biomarkers in training. Yet, as before, we assume that only
the baseline MRI scan is available for testing subjects.
Adding a time-varying biomarker is relatively easy in our
model, as it involves adding another target variable type.
This target variable will have its own inflection point and
observation model (Equation 3). Note that in our frame-
work, due to the conditional independence assumptions, in-
ference is robust to the timing and availability of the target
variables. During training (i.e., when optimizing the ELBO
function), the algorithm simply sums over all available visits
and evaluates the function only for observed targets.
Fig. 4 shows the performance of our model trained with
and without longitudinal MRI scans. We observe that pre-
diction accuracy is consistently better when trained with
longitudinal MRI scans, which suggests that we can improve
the quality of the model’s predictions by incorporating ad-
ditional time-varying biomarkers.
3.4 Further Analysis of the Proposed Model
The proposed model can be viewed as a generative prob-
abilistic model that gives rise to clinical assessments and
possibly other time-varying biomarkers. Hence, in addition
to computing individual-level predictions, we can probe the
trained model to gain further insights about the underly-
Figure 2: Absolute error (mean and standard derivation) of all methods for predicting MMSE, ADAS-COG and CDRSB, as
a function of number of past visits available on test subjects.
Figure 3: Absolute error (mean and standard derivation) of all methods for predicting MMSE, ADAS-COG and CDRSB. We
used two points from each test subject as past observations and varied the time horizon for prediction.
ing dynamics of the pathology. In this section, we provide
examples of such analyses.
3.4.1 Inflection Points
In our model, each target variable is associated with a latent
sigmoid curve that captures temporal dynamics. While the
slope of these sigmoids are coupled across target variables,
their inflection points pk are different. Yet, we emphasize
that the inflection points are not assumed to be independent
across targets, as they are drawn from a prior distribution
shaped by the subject’s attributes xi (see Eq. 1). For a
given subject, the difference between the inflection points of
a pair of target variables reflects the time lag between the
corresponding progression curves.
After we fit the proposed model on the training data, we
draw samples for the unobserved inflection points on test
data. We then empirically estimated the prior distribution
of pk averaged across subjects via a kernel density estimator
(Gaussian kernel with variance = 2.5). Fig. 5 plots the em-
pirical prior distributions for the different target variables
and their latent progression curves corresponding to the
mean parameter values (for the slope and inflection points)
derived from the empirical priors.
We notice that the MMSE progression, on average, is ear-
lier than ADAS-COG, with a mean difference of around
3.5 years. ADAS-COG is, in turn, on average, about 11
years earlier than CDR-SB. These results are consistent with
the hypothesized trajectories of AD biomarkers [11], where
memory and cognitive scores such as MMSE and ADAS-
COG start declining sooner than clinical symptoms.
3.4.2 The Impact of APOE, Sex, and Education
Next, we were interested in inspecting how APOE, sex, and
education impact the trajectories MMSE, ADAS-COG and
CDRSB. In our model, the parameter vector w determines
the mean slope and v affects the mean inflection point of the
latent progression curves. Table 2 lists the estimated values
in w and v (averaged over the 20 folds) for APOE, sex,
and education. We observe that each extra APOE E4 al-
lele copy increases the maximum rate of progression (which
is equal to si/4) by an additional 24.5%, yet shifts the in-
flection forward by 0.11 years. Males, on average, have a
maximum rate of progression that is 9.25% more than fe-
males, and their inflection points are 0.31 years later. Each
additional decade of education, on the other hand, delays
the progression curves by 0.44 years, yet the maximum rate
of progression increases by an additional 8.1%.
Table 2: Average estimates for w and v corresponding to
APOE, sex, and education
APOE Sex Edu
(E4 Count) (0: female, 1: male) (decades)
w 0.98 0.38 0.33
v 0.11 0.31 0.44
3.4.3 Visualization of Personalized Models
As we discussed above, the proposed model can adjust its
predictions based on available observations on the test data.
In this section, we were interested in revealing this person-
alization effect on subject-specific trajectories. In Figure 6,
we visualized the predicted trajectories for MMSE, ADAS-
COG and CDRSB on several representative subjects, under
two conditions: no past visits and four past visits. Note
that we chose the subjects from 6 sub-groups: stable HC,
stable MCI, stable AD, HC-to-MCI converter, MCI-to-AD
converter, and HC-to-AD converter. In each sub-group,
we selected representative subjects with most time-points.
Figure 6 visualizes the ground truth clinical scores, which
are marked with x’s. Those points that are circled with
green are considered observed past points in the second con-
Figure 4: The mean absolute errors with standard derivation of our method on MMSE prediction computed from 20-fold
cross-validation with longitudinal MR images in training process and without. We varies the number of past visits from 0 to
4 to evaluate how our methods adapt to use different priors from past visits to improve the performance.
Figure 5: Left: empirically estimated prior distributions of
the inflection points for the three clinical target variables.
Right: Mean latent progression curves for the different tar-
gets.
dition to compute the adjusted projections (personalized
model). We observe that the baseline model predictions
(corresponding to no past visit and illustrated in blue) are
often much less accurate than the personalized model (red).
The baseline model, in general, predicts little change over
time, whereas the personalized model offers better projec-
tions that can capture significant change.
4. DISCUSSION
We presented a probabilistic, latent disease progression model
for capturing the dynamics of the underlying pathology that
is often shaped by risk factors such as genotype. Our work
is motived by real-world clinical applications, where irreg-
ular visiting patterns, missing variables, and inconsistent
multi-modal assessments are ubiquitous. In the proposed
framework, we make a distinction between subject-level at-
tributes, which we assume are fixed, and time-varying clin-
ical observations, which can include imaging and cognitive
tests, collected over multiple visits. These time-varying vari-
ables are modeled to be noisy observations of an idealized
latent, sigmoid progression curve that has two parameters:
its inflection point and slope. These parameters are in turn,
assumed to be functions of the fixed subject attributes. We
take a Bayesian approach to fit this model on a training
dataset with clinical observations, where the parameters of
the latent progression curve is integrated out.
In this work, we had two distinct, yet simultaneous goals.
Our first goal was practical: to forecast the clinical future
of a test subject based on a population model that is cus-
tomized if we have historical observations from the test sub-
ject. Our second goal was “knowledge discovery:” we were
interested in gaining insights about the underlying dynam-
ics of various clinical assessments and further identifying the
impact of risk factors such as genotype.
We applied the proposed method on a large dataset of Alzheimer’s
disease with promising results. In our experiments, we ana-
lyzed prediction accuracy for the proposed model and several
benchmark methods under different scenarios that included
varying the known patient history and prediction horizon.
In all our comparisons, the proposed model achieved the best
performance. However, we caution the author to treat these
results as preliminary. In future work, we are interested
in exploring methods that might yield better prediction ac-
curacy. One approach would be to exploit more input vari-
ables, such as genome-wide markers and whole-brain images.
Such high-dimensional models will likely require additional
prior constraints, such as sparsity, to avoid overfitting, as
in [32; 30]. Another, closely related framework is multi-task
learning, which is suitable for our problem of predicting mul-
tiple clinical target variables. Multi-task learning has been
applied to predict multiple correlated diseases [21], integrate
data from several sources [28] or modalities [31]. However,
in prior works, the target variables are often considered fixed
and/or longitudinal observations are ignored.
Another direction that will likely yield improved accuracy
is to extend our model beyond linearity assumptions. Deep
learning techniques, such as reccurent neural networks (RNNs),
offer a natural framework for this direction. RNNs have
been applied to related problems, such as clinical diagnosis
from time-series data [14; 6], and imputing missing longitu-
dinal variables [13]. The main challenge in these approaches
is that they are often data hungry (requiring lots of anno-
tated data to train on) and hard to interpret, which conflicts
with our objective to obtain interpretable insights about un-
derlying disease dynamics. Furthermore, RNN models usu-
ally assume fixed intervals between time-points - an assump-
tion widely violated in real-life scenarios. In contrast, our
Bayesian approach is flexible, assumes no regularity in visit
times, does not need a huge amount of data to fit, can seam-
lessly handle multiple modalities, and, importantly, yields
straightforward interpretations.
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In our experiments, we employed data downloaded from the
longitudinal ADNI study (phases 1, GO, and 2, adni.loni.usc.edu) [23],
based on the data derived for the Tadpole 2017 Challenge
(https://tadpole.grand-challenge.org/home/). Scripts to gen-
erate these data from ADNI can found here:
https://github.com/noxtoby/TADPOLE.
The ADNI was launched in 2003 as a public-private part-
nership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether
serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to mea-
sure the progression of mild cognitive impairment (MCI) and
early Alzheimers disease (AD). For up-to-date information,
see www.adni-info.org.
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Figure 6: Visualization of predicted (solid line, posterior mean) MMSE, ADAS-COG and CDRSB curves for various represen-
tative subjects. One standard deviation of predictions are illustrated with shaded area (68.2% confidence interval). Clinical
assessments are indictated with x. The proposed model was used under two conditions: with no prior visits (blue, baseline)
and with the first four visits (green circles) treated as test observations (red, personalized). The ground truth future visits
are denoted by orange rectangles. See text for further details.
